Susquehanna International Group
FATE icon

Susquehanna International Group’s Fate Therapeutics FATE Stock Holding History

Susquehanna International Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.8K Sell
31,500
-44,400
-58% -$54.1K ﹤0.01% 12703
2025
Q4 		$74.4K Buy
+75,900
New +$91.1K ﹤0.01% 11597
2024
Q2 		– Sell
-39,000
Closed -$286K – 12342
2024
Q1 		$286K Buy
+39,000
New +$241K ﹤0.01% 9803
2023
Q3 		– Sell
-31,800
Closed -$151K – 12267
2023
Q2 		$151K Buy
31,800
+21,500
+209% +$119K ﹤0.01% 10564
2023
Q1 		$58.7K Buy
+10,300
New +$62.1K ﹤0.01% 11625
2022
Q4 		– Sell
-12,200
Closed -$273K – 12766
2022
Q3 		$273K Sell
12,200
-84,300
-87% -$2.44M ﹤0.01% 10033
2022
Q2 		$2.39M Buy
96,500
+68,300
+242% +$1.88M ﹤0.01% 4530
2022
Q1 		$1.09M Sell
28,200
-11,600
-29% -$449K ﹤0.01% 6879
2021
Q4 		$2.33M Sell
39,800
-110,900
-74% -$6.29M ﹤0.01% 5145
2021
Q3 		$8.93M Buy
150,700
+83,400
+124% +$6.54M ﹤0.01% 3032
2021
Q2 		$5.84M Sell
67,300
-48,700
-42% -$3.92M ﹤0.01% 3742
2021
Q1 		$9.56M Buy
116,000
+57,400
+98% +$5.5M ﹤0.01% 2838
2020
Q4 		$5.33M Sell
58,600
-40,800
-41% -$2.53M ﹤0.01% 3320
2020
Q3 		$3.97M Sell
99,400
-11,100
-10% -$388K ﹤0.01% 3382
2020
Q2 		$3.79M Buy
110,500
+39,800
+56% +$1.19M ﹤0.01% 3411
2020
Q1 		$1.57M Sell
70,700
-234,100
-77% -$5.92M ﹤0.01% 4413
2019
Q4 		$5.96M Buy
304,800
+91,500
+43% +$1.45M ﹤0.01% 2735
2019
Q3 		$3.31M Buy
213,300
+40,800
+24% +$782K ﹤0.01% 3329
2019
Q2 		$3.5M Sell
172,500
-15,800
-8% -$285K ﹤0.01% 3221
2019
Q1 		$3.31M Buy
188,300
+82,500
+78% +$1.3M ﹤0.01% 2992
2018
Q4 		$1.36M Buy
105,800
+38,000
+56% +$530K ﹤0.01% 4151
2018
Q3 		$1.1M Buy
67,800
+25,200
+59% +$298K ﹤0.01% 5032
2018
Q2 		$483K Buy
42,600
+13,200
+45% +$145K ﹤0.01% 6862
2018
Q1 		$287K Buy
+29,400
New +$282K ﹤0.01% 7703

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's FATE Position: Q1 2026 in Review

Susquehanna International Group reduced its Fate Therapeutics (FATE) stake by 3.8% in Q1 2026, selling an estimated $14.2K and leaving 298,496 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #10473.

Susquehanna International Group first reported a position in FATE in Q4 2017 and has held it in 31 quarters since. The position peaked at $6.44M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Susquehanna International Group held 298,496 shares of Fate Therapeutics worth $358K as of Q1 2026.
  • Susquehanna International Group sold 11,695 Fate Therapeutics shares in Q1 2026, an estimated $14.2K.
  • Fate Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10473 holding.
  • Susquehanna International Group first reported a position in Fate Therapeutics in Q4 2017 and has held it in 31 quarters since.
  • Susquehanna International Group's Fate Therapeutics position peaked at $6.44M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.